Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIUD Alone or With Everolimus in Atypical Hyperplasia and Endometrial Cancer
NCT02397083Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2015
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avatrombopag, everolimus in Atypical endometrial hyperplasia (AEH), endometrial cancer (EC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2015; status: active, not recruiting.
02
Drugs
avatrombopageverolimus
03
Conditions
Atypical endometrial hyperplasia (AEH)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02397083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397083.